A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.

ABSTRACT:

Purpose

Recurrent platinum-resistant ovarian cancer has no curative options, necessitating the development of novel treatments, including immunotherapy.

Rationale

Patient-derived T cells can be genetically modified to express chimeric antigen receptors (CARs) specific to tumor-associated antigens in an HLA-independent manner, with promising preclinical results. MUC16(ecto) is highly expressed on most epithelial ovarian carcinomas but at low levels on normal tissues, offering an excellent immunotherapeutic target for this cancer. CAR T cells further modified to secrete IL-12 show enhanced cytotoxicity, persistence, and modulation of the tumor microenvironment.

Design

We propose a dose escalation phase I clinical trial for patients with recurrent MUC-16(ecto+) ovarian c

SUBMITTER: Koneru M 

PROVIDER: S-EPMC4438636 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature